Pierreione BCAS# 1292766-21-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1292766-21-2 | SDF | Download SDF |
| PubChem ID | 52951514 | Appearance | Powder |
| Formula | C26H28O7 | M.Wt | 452.50 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 7-[4-[(2R)-2,3-dihydroxy-3-methylbutoxy]-3-methoxyphenyl]-2,2-dimethylpyrano[3,2-g]chromen-6-one | ||
| SMILES | CC1(C=CC2=C(O1)C=C3C(=C2)C(=O)C(=CO3)C4=CC(=C(C=C4)OCC(C(C)(C)O)O)OC)C | ||
| Standard InChIKey | RDXLWAJRBPKMPD-HSZRJFAPSA-N | ||
| Standard InChI | InChI=1S/C26H28O7/c1-25(2)9-8-16-10-17-21(12-20(16)33-25)31-13-18(24(17)28)15-6-7-19(22(11-15)30-5)32-14-23(27)26(3,4)29/h6-13,23,27,29H,14H2,1-5H3/t23-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Pierreione B is an inhibitor of mTOR signaling with strong anticancer activity. 2. Pierreione A and Pierreione B demonstrate solid tumor selectivity with minimal cytotoxicity. |
| Targets | mTOR |
Pierreione B Dilution Calculator
Pierreione B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2099 mL | 11.0497 mL | 22.0994 mL | 44.1989 mL | 55.2486 mL |
| 5 mM | 0.442 mL | 2.2099 mL | 4.4199 mL | 8.8398 mL | 11.0497 mL |
| 10 mM | 0.221 mL | 1.105 mL | 2.2099 mL | 4.4199 mL | 5.5249 mL |
| 50 mM | 0.0442 mL | 0.221 mL | 0.442 mL | 0.884 mL | 1.105 mL |
| 100 mM | 0.0221 mL | 0.1105 mL | 0.221 mL | 0.442 mL | 0.5525 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Perospirone hydrochloride
Catalog No.:BCC9118
CAS No.:129273-38-7
- Hoechst 33258 analog 6
Catalog No.:BCC1628
CAS No.:129244-66-2
- IKKε-IN-1
Catalog No.:BCC5514
CAS No.:1292310-49-6
- 15-Dihydroepioxylubimin
Catalog No.:BCN4800
CAS No.:129214-59-1
- (2S,3S)-(-)-Glucodistylin
Catalog No.:BCN6156
CAS No.:129212-92-6
- Iberiotoxin
Catalog No.:BCC6932
CAS No.:129203-60-7
- Biotin-HPDP
Catalog No.:BCC3583
CAS No.:129179-83-5
- Gancaonin M
Catalog No.:BCN4757
CAS No.:129145-51-3
- 2-(2,2-Dimethyl-1,3-dioxolan-4-yl)propane-1,2-diol
Catalog No.:BCC8475
CAS No.:129141-48-6
- CGRP 8-37 (rat)
Catalog No.:BCC5717
CAS No.:129121-73-9
- ENMD-2076 L-(+)-Tartaric acid
Catalog No.:BCC2185
CAS No.:1291074-87-7
- Evodosin A
Catalog No.:BCN7322
CAS No.:1291053-38-7
- Boscialin
Catalog No.:BCN7323
CAS No.:129277-03-8
- PF-2545920
Catalog No.:BCC2279
CAS No.:1292799-56-4
- Semilicoisoflavone B
Catalog No.:BCN2931
CAS No.:129280-33-7
- Isoangustone A
Catalog No.:BCN6819
CAS No.:129280-34-8
- Licorisoflavan A
Catalog No.:BCN6662
CAS No.:129314-37-0
- Alendronate sodium
Catalog No.:BCC3719
CAS No.:129318-43-0
- O-Geranylconiferyl alcohol
Catalog No.:BCN4747
CAS No.:129350-09-0
- 11-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one
Catalog No.:BCC8430
CAS No.:129385-59-7
- Physcion 8-O-rutinoside
Catalog No.:BCN7324
CAS No.:129393-21-1
- Euphorbia factor L9
Catalog No.:BCN3786
CAS No.:129393-28-8
- Fmoc-Phenylalaninol
Catalog No.:BCC2717
CAS No.:129397-83-7
- Boc-Cysteinol(pMeBzl)
Catalog No.:BCC3044
CAS No.:129397-85-9
Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.[Pubmed:23934262]
Cancer Chemother Pharmacol. 2013 Oct;72(4):799-808.
PURPOSE: Mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in regulating cell growth, proliferation and survival. Dysregulation of mTOR signaling pathway is closely involved in cancer development and chemotherapy resistance. Inhibitors of mTOR signaling pathway have been demonstrated to be attractive therapeutics for cancer therapy. In the present study, we aim to discover novel mTOR signaling pathway inhibitors from a natural compound library. METHODS: Inhibitors of mTOR signaling pathway were discovered via high content screen assay based on the subcellular localization of eukaryotic initiation factor 4E (eIF4E) in mouse embryonic fibroblast cells. Candidate compounds were further assessed in cancer cells. Phosphorylation levels of mTOR complexes downstream targets were analyzed using Western blot. Cell cytotoxicity and apoptosis were evaluated using MTS assay and flow cytometry, respectively. RESULTS: Two compounds, 1,4-O-diferuloylsecoisolariciresinol (IM-1) and Pierreione B (IM-2), were identified which induced significant nuclear translocation of eIF4E in a panel of cancer cells. Both of the compounds decreased the phosphorylation levels of p70 ribosomal protein S6 kinase (S6K) and eIF4E binding protein 1 (4E-BP1), resulting in cancer cell cytotoxicity and apoptosis. CONCLUSIONS: Via high content screen assay, two novel inhibitors of mTOR signaling, IM-1 and IM-2, were identified with strong anticancer activity. IM-1 and IM-2 could be potential candidates for anticancer therapeutics by targeting mTOR signaling pathway and as such warrants further exploration.
